ID Technology API Therapeutic Area Administration Formulation Pre-clinical Phase 1 Phase 2 Partner
MTX110 MidaSolve Panobinostat Glioblastoma Direct to tumour via CED
MTX110 MidaSolve Panobinostat Brain Cancer in Children (DIPG) Direct to tumour via CED
MTX110 MidaSolve Panobinostat Medulloblastoma Direct to tumour
MTX114 MidaCore™ Methotrexate Psoriasis Topical
MTD211 Q-Sphera™ Brexpiprazole Schizophrenia, MDD Long Acting Injectable
MTD219 Q-Sphera™ Tacrolimus Prophylaxis, transplant rejection Long Acting injectable
MTX213 Q-Sphera™ undisclosed undisclosed Long Acting Injectable
MTX223 Q-Sphera™ undisclosed undisclosed Long Acting Injectable

Biodexa Pharmaceuticals is a clinical stage biopharmaceutical company developing a pipeline of products aimed at primary and metastatic cancers of the brain.


Biodexa Pharmaceuticals Q-Sphera™ technology focusses on long acting injectables using proprietary 3D printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics.

In partnership, we use our rapid R&D innovation to enable drugs to reach areas of the body where they are needed and to exert their actions in an tuneable, effective, and precise manner.


MidaCore™ technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The small size and multi-functional arrangement of molecules around a gold core underpin MidaCore’s ability to improve biodistribution and targeted drug delivery.


MidaSolve Nano Inclusion technology solubilises potent molecules that have minimal solubility at biological pH extending available routes of administration, including direct-to-tumour delivery.

Biodexa Pharmaceuticals is developing an internal asset pipeline across high value markets and areas of unmet clinical need in addition to progressing additional Pharma and Biotech Q-Sphera based collaborations.

Expanded Access Policy

View Expanded Access Policy